Trial Profile
Phase II Study of Age-Adjusted R-BAC (Rituximab, Bendamustine, Cytarabine) as Induction Therapy in Older Patients With Mantle Cell Lymphoma (MCL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2023
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms FIL-RBAC500
- 12 Oct 2017 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Final results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 08 Aug 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.